Fresenius SE & Co. (OTCMKTS:FSNUY – Get Free Report) issued its quarterly earnings results on Wednesday. The company reported $0.24 EPS for the quarter, missing the consensus estimate of $0.25 by ($0.01), Zacks reports. The business had revenue of $6.75 billion during the quarter, compared to the consensus estimate of $6.79 billion. Fresenius SE & Co. had a return on equity of 10.29% and a net margin of 6.55%.
Fresenius SE & Co. Stock Performance
Shares of FSNUY stock traded up $0.24 during mid-day trading on Friday, reaching $12.27. The stock had a trading volume of 85,353 shares, compared to its average volume of 93,401. Fresenius SE & Co. has a one year low of $11.28 and a one year high of $33.93. The firm has a market cap of $27.64 billion, a PE ratio of 16.36 and a beta of 0.68. The firm’s 50 day simple moving average is $13.07 and its 200 day simple moving average is $14.14. The company has a quick ratio of 1.00, a current ratio of 1.32 and a debt-to-equity ratio of 0.47.
Wall Street Analyst Weigh In
Several research analysts have commented on the stock. Morgan Stanley reiterated an “overweight” rating on shares of Fresenius SE & Co. in a report on Monday, April 20th. Citigroup reaffirmed a “buy” rating on shares of Fresenius SE & Co. in a research note on Tuesday, February 3rd. Three analysts have rated the stock with a Buy rating, According to MarketBeat, Fresenius SE & Co. currently has a consensus rating of “Buy”.
About Fresenius SE & Co.
Fresenius SE & Co KGaA is a global healthcare group headquartered in Bad Homburg vor der Höhe, Germany. Founded in 1912 by Eduard Fresenius, the company has grown into one of the world’s leading providers of products and services for dialysis, hospitals and outpatient medical care. Trading on major European exchanges and available over the counter in the U.S. as FSNUY, Fresenius SE & Co brings together a portfolio of specialized healthcare businesses under one corporate umbrella.
The company operates through four main business segments.
Further Reading
Receive News & Ratings for Fresenius SE & Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius SE & Co. and related companies with MarketBeat.com's FREE daily email newsletter.
